|
| Drug combination | Cancer/cell line | Effect | Refs |
|
| DHA + Temozolomide | Rat C6 glioma cells | Increased apoptosis, ROS
Induced necrosis | [107] |
|
| DHA + Cyclophosphamide | Lewis lung carcinoma | Increased apoptosis, decreased VEGF receptor KDR/flk-1
Apoptosis | [84] |
|
| DHA + Cisplatin | Human non-small cell lung cancer (A549) | Decreased metastasis | [84] |
|
| DHA + Gemcitabine | Pancreas (Panc-1)
| Inhibition of proliferation, decreased cyclin D1
Increased apoptosis, increased Bax/Bcl2 ratio, activation of caspase 3 | [94] |
| Hepatoma (cell panel) | Increased growth inhibition by 45% | [67] |
|
| DHA + Butyric acid | Human lymphoblastoid leukemia (Molt-4) | Synergistic. Depletion of cancer cells | [110] |
|
| DHA + Radiation | Glioma cells
U373MG | Increased cytotoxicity
Inhibition of radiation-induced GST | [53] |
|
| DHA + Carboplatin | Ovarian cancer cells (A2780, OVCAR-3) | Increased growth inhibition through death receptor and mitochondrial mediated pathways | [77] |
|
| DHA + TRAIL | Prostate cancer (DU145, PC-3, LNCaP) | Increased apoptosis extrinsic and intrinsic pathways | [100] |
|
| ART/DHA + Doxorubicin + Pirarubicin | Leukemia (K562/adr)
Small cell lung cancer (GLC4/adr) | Synergistic | [4] |
|
| ART + Lenalidomide | Lung (A549) and breast (MCF-7) | Decreased IC50 by 48% | [111] |
|
| ART + Oxiplatin | Colon (HT 1116) | Additive. Sensitising effect |
[111] |
| ART + Gemcitabine | Breast (MCF-7) | Additive |
| Lung (A549) | Additive |
|
ATM + Oxiplatin
ATM + Thalidomide
ATM + Gemcitabine
| Colon (HCTl16, SW480)
Breast (MCF-7) | All additive | [63] |
|
| ARS + Hyperbaric oxygen (HBO2) | Molt-4 human leukemia | 22% decrease in growth | [112] |
|
| ARS + Doxorubicin | Colon cancer(HT29) | Predicted as antagonic, mediated by activation of NF-κB/overexpression of Pgp | [59] |
|
| ARS + Oxiplatin | Colon (HCTl16, SW480) | Antagonism |
[63] |
| ARS + Thalidomide | Additive |
| ARS + Gemcitabine | Breast (MCF-7) | Antagonism |
|